EWING, N.J., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the 28 th Annual Piper Jaffray Healthcare Conference on Wednesday November 30, 2016 at 3:30 pm, Eastern Time. A live webcast of the presentation will be available via the webcast tab under the Investor Information page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation. About Antares Pharma Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company's product, OTREXUP® (methotrexate) injection for subcutaneous use, is approved in the U.S. for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. The Company and Teva Pharmaceutical Industries, Ltd. (Teva) recently announced the third quarter 2016 U.S. commercial launch of VIBEX ® Sumatriptan Injection USP for the acute treatment of migraine and cluster headache. Antares Pharma is also developing QuickShot ® Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX ® disposable auto injectors, disposable multi-use pen injectors and reusable needle-free injectors. Antares Pharma has a multi-product deal with Teva that includes VIBEX ® epinephrine, exenatide multi-dose pen, and teriparatide multi-dose pen. Our reusable needle-free injector for use with human growth hormone (hGH) is sold worldwide by Ferring B.V. The Company is also working with AMAG Pharmaceuticals on a subcutaneous method of administering Makena, a progesterone product indicated for use in lowering the risk of pre-term birth. For more information, visit www.antarespharma.com.